Research graph
References from A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [ 177 Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA). Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(24)01653-2
10.1016/s0140-6736(24)01653-2 · External reference
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
10.1016/s0140-6736(21)00237-3
10.1016/s0140-6736(21)00237-3 · External reference
LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 [abstract]
10.1016/j.annonc.2025.09.105 · 2025 · External reference
10.1016/j.clgc.2018.09.014
10.1016/j.clgc.2018.09.014 · External reference
10.1016/s1470-2045(18)30198-0
10.1016/s1470-2045(18)30198-0 · External reference
10.2967/jnumed.118.219352
10.2967/jnumed.118.219352 · External reference
Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) [abstract]
10.1200/jco.2024.42.16_suppl.5074 · 2024 · External reference
10.2967/jnumed.122.264104
10.2967/jnumed.122.264104 · External reference
10.2967/jnumed.121.262552
10.2967/jnumed.121.262552 · External reference
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling
10.1038/s41392-023-01639-6 · 2023 · External reference
10.2967/jnumed.120.256263
10.2967/jnumed.120.256263 · External reference
10.1007/s11307-023-01857-y
10.1007/s11307-023-01857-y · External reference
10.1016/s1470-2045(22)00605-2
10.1016/s1470-2045(22)00605-2 · External reference
10.2967/jnumed.122.265242
10.2967/jnumed.122.265242 · External reference
10.2967/jnumed.123.267014
10.2967/jnumed.123.267014 · External reference
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
10.1016/s1470-2045(25)00339-0 · 2025 · External reference
177Lu-DOTA-HYNIC-Lys(Nal)-urea-Glu: biokinetics, dosimetry, and evaluation in patients with advanced prostate cancer
10.1155/2018/5247153 · 2018 · External reference
PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression
10.1080/23723556.2017.1321168 · 2017 · External reference
10.2967/jnumed.118.223099
10.2967/jnumed.118.223099 · External reference
10.1084/jem.20171052
10.1084/jem.20171052 · External reference
Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer
10.1158/1078-0432.ccr-21-4531 · 2022 · External reference
DNA damage in blood leukocytes of prostate cancer patients undergoing PET/CT examinations with [68Ga]Ga-PSMA I&T
10.3390/cancers12020388 · 2020 · External reference
10.2967/jnumed.124.267452
10.2967/jnumed.124.267452 · External reference
